GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avrobio Inc (NAS:AVRO) » Definitions » 5-Day RSI

Avrobio (Avrobio) 5-Day RSI : 73.35 (As of Jun. 10, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Avrobio 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-06-10), Avrobio's 5-Day RSI is 73.35.

The industry rank for Avrobio's 5-Day RSI or its related term are showing as below:

AVRO's 5-Day RSI is ranked worse than
89.96% of 1563 companies
in the Biotechnology industry
Industry Median: 42.75 vs AVRO: 73.35

Competitive Comparison of Avrobio's 5-Day RSI

For the Biotechnology subindustry, Avrobio's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avrobio's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avrobio's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Avrobio's 5-Day RSI falls into.



Avrobio  (NAS:AVRO) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avrobio  (NAS:AVRO) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Avrobio 5-Day RSI Related Terms

Thank you for viewing the detailed overview of Avrobio's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Avrobio (Avrobio) Business Description

Traded in Other Exchanges
N/A
Address
100 Technology Square, Sixth Floor, Cambridge, MA, USA, 02139
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.
Executives
Azadeh Golipour officer: Chief Technology Officer ONE KENDALL SQUARE, BLD. 300 - SUITE 201, CAMBRIDGE MA 02139
Essra Ridha officer: Chief Medical Officer C/O AVROBIO, INC., ONE KENDALL SQUARE, BLDG 300 - SUITE 201, CAMBRIDGE MA 02139
Philip J. Vickers director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Christopher Mason officer: Chief Scientific Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Phillip B. Donenberg director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Diana Escolar officer: Chief Medical Officer C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Gail M Farfel director 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Deanna M Petersen officer: Chief Business Officer 45 FIRST AVENUE, WALTHAM MA 02451
Geoffrey Mackay director, officer: See Remarks C/O AVROBIO, INC., ONE KENDALL SQ, BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Christopher Paige director C/O AVROBIO INC, ONE KENDALL SQ, BLDG 300, STE 201, CAMBRIDGE MA 02139
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, Llc other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p. other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund I, L.p. other: See Remarks 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451